Last reviewed · How we verify
clopidogrel combined with rivaroxaban arm
Clopidogrel combined with rivaroxaban, marketed by Shenyang Northern Hospital, holds a unique position in the cardiovascular and anticoagulant market. The key composition patent expiring in 2028 provides a significant period of exclusivity, enhancing the drug's competitive advantage. However, the lack of detailed primary trial results and revenue data poses a primary risk, potentially limiting investor confidence and market adoption.
At a glance
| Generic name | clopidogrel combined with rivaroxaban arm |
|---|---|
| Also known as | clopidogrel combined with rivaroxaban |
| Sponsor | Shenyang Northern Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: